163 related articles for article (PubMed ID: 38688627)
1. Quetiapine Significantly Improves the Effectiveness of Radiotherapy in Combating Hepatocellular Carcinoma Progression in a Hep3B Xenograft Mouse Model.
Yang JD; Liu YC; Wang HC; Hsu FT; Liao TL; Huang MC; Chen JH
In Vivo; 2024; 38(3):1079-1093. PubMed ID: 38688627
[TBL] [Abstract][Full Text] [Related]
2. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
[TBL] [Abstract][Full Text] [Related]
3. The inhibitory effect and mechanism of quetiapine on tumor progression in hepatocellular carcinoma in vivo.
Su CM; Lin SS; Wang HC; Hsu FT; Chung JG; Hsu LC
Environ Toxicol; 2022 Jan; 37(1):92-100. PubMed ID: 34626444
[TBL] [Abstract][Full Text] [Related]
4. ERK/AKT Inactivation and Apoptosis Induction Associate With Quetiapine-inhibited Cell Survival and Invasion in Hepatocellular Carcinoma Cells.
Lee YJ; Chung JG; Tan ZL; Hsu FT; Liu YC; Lin SS
In Vivo; 2020; 34(5):2407-2417. PubMed ID: 32871766
[TBL] [Abstract][Full Text] [Related]
5. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
[TBL] [Abstract][Full Text] [Related]
6. UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation.
Sun J; Zhu Z; Li W; Shen M; Cao C; Sun Q; Guo Z; Liu L; Wu D
J Exp Clin Cancer Res; 2020 Oct; 39(1):222. PubMed ID: 33087136
[TBL] [Abstract][Full Text] [Related]
7. Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma.
Guo L; Li H; Fan T; Ma Y; Wang L
Life Sci; 2021 Aug; 279():119359. PubMed ID: 33753114
[TBL] [Abstract][Full Text] [Related]
8. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
Huynh H; Ong R; Soo KC
Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation.
Ding H; Liu J; Zou R; Cheng P; Su Y
J Exp Clin Cancer Res; 2019 May; 38(1):189. PubMed ID: 31072375
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
12. Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway.
Zhao S; Xu K; Jiang R; Li DY; Guo XX; Zhou P; Tang JF; Li LS; Zeng D; Hu L; Ran JH; Li J; Chen DL
Life Sci; 2020 Jun; 251():117424. PubMed ID: 32057900
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice.
Weng MC; Wang MH; Tsai JJ; Kuo YC; Liu YC; Hsu FT; Wang HE
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29535278
[TBL] [Abstract][Full Text] [Related]
14. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma.
Liao J; Jin H; Li S; Xu L; Peng Z; Wei G; Long J; Guo Y; Kuang M; Zhou Q; Peng S
J Exp Clin Cancer Res; 2019 Nov; 38(1):454. PubMed ID: 31694662
[TBL] [Abstract][Full Text] [Related]
15. Auphen and dibutyryl cAMP suppress growth of hepatocellular carcinoma by regulating expression of aquaporins 3 and 9 in vivo.
Peng R; Zhao GX; Li J; Zhang Y; Shen XZ; Wang JY; Sun JY
World J Gastroenterol; 2016 Mar; 22(12):3341-54. PubMed ID: 27022216
[TBL] [Abstract][Full Text] [Related]
16. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
17. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
You ML; Chen YJ; Chong QY; Wu MM; Pandey V; Chen RM; Liu L; Ma L; Wu ZS; Zhu T; Lobie PE
Oncotarget; 2017 Jun; 8(24):39323-39344. PubMed ID: 28445151
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
19. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of Radiation Response Associated With Metformin in Hepatocellular Carcinoma: Preclinical Animal and Clinical Cohort Study.
Jang WI; Kim MS; Jeong JH; Kim W; Kim JS
Anticancer Res; 2022 Feb; 42(2):867-876. PubMed ID: 35093884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
